OpenAI brings frontier models and Codex workflows to Google Cloud, while Tenstorrent lands $1.5 billion and Pathos AI secures $237 million to accelerate chips and drug discovery. Meta acquires Sundial to sharpen AI analytics, raising the stakes for enterprise intelligence. Scroll down to catch the signals that matter.

🏠 Archie Engine 1.3 Brings Local AI to Real Estate

ArchieVerse.ai’s Archie Engine 1.3 beta runs on compatible devices, helping agents prepare listings, create marketing images and videos, generate property comps, produce public CMAs, and coordinate showings. Local processing could give real-estate professionals faster, more context-aware assistance while reducing dependence on centralized workflows and external tools.

Local AI is moving from experimentation into daily property marketing and operations.

☁️ OpenAI Models Enter Google Cloud’s Marketplace

OpenAI’s Google Cloud partnership will bring frontier models and Codex agentic workflows into Model Garden. Enterprises can purchase them through Google Cloud Marketplace, apply existing platform commitments, and combine OpenAI capabilities with Google’s governance, infrastructure, and enterprise procurement systems.

Cloud distribution is becoming a decisive battleground for enterprise AI adoption.

🧠 Meta Acquires AI Analytics Company

Meta’s AI analytics acquisition strengthens its internal intelligence capabilities by bringing specialized analytics talent and technology into the company. The move signals a push toward AI-powered data tooling and agents that can improve how Meta interprets information, supports decision-making, and operates complex platforms.

The next AI advantage may come from better internal data intelligence, not just bigger models.

🧬 Tempus AI Expands Bristol Myers Squibb Oncology Partnership

Tempus AI’s expanded Bristol Myers Squibb partnership adds multi-year oncology data licensing and access to Tempus’s AI platform. The arrangement deepens collaboration between clinical-data infrastructure and pharmaceutical research, potentially helping teams identify treatment insights, improve development decisions, and accelerate precision-oncology programs.

AI-powered clinical data is becoming a strategic asset in drug development.

💸 Neoclouds Draw Record AI Investment

PitchBook data reported record neocloud funding, with $6.6 billion invested across 58 deals. These specialized infrastructure providers are attracting capital by offering AI-focused compute, flexible access, and alternatives to traditional hyperscaler capacity as demand for training and inference continues pressuring the global chip supply chain.

Investors are betting that AI infrastructure will need more specialized providers than hyperscalers alone can deliver.

⚡ Tenstorrent Lands $1.5 Billion Series E

AI chip startup Tenstorrent closed a record $1.5 billion Series E at an approximately $6.2 billion valuation. The financing gives the company substantial room to develop competing AI hardware, expand engineering and manufacturing efforts, and challenge incumbent accelerator strategies built around tightly integrated software ecosystems.

Massive private funding is intensifying the race for credible alternatives in AI silicon.

🧪 Pathos AI Raises $237 Million for Drug Discovery

Pathos AI secured a $237 million Series E at an approximately $3 billion valuation to scale its artificial-intelligence drug-development platform and therapeutic pipeline. The capital can support research programs, platform improvements, and the translation of computational discoveries into candidates that advance through costly biological validation and development stages.

AI drug discovery is attracting funding at valuations that reflect long-term therapeutic ambitions.

🔬 Pathos AI Expands Its Therapeutic Pipeline

Pathos AI’s new investment provides $237 million to expand its AI-driven drug-development platform and advance therapeutic programs. By combining machine learning with biological research, the company aims to improve target discovery and candidate selection while building a pipeline designed to address complex diseases more efficiently.

The strongest AI-biotech stories now depend on turning platform claims into clinical progress.

🛰️ Weflayr Raises $2.5 Million for Inference Routing

Weflayr secured $2.5 million in pre-seed funding to develop AI inference-routing technology. Its approach targets how requests move across models and infrastructure, an increasingly important challenge as organizations balance latency, cost, reliability, and performance across diverse workloads and deployment environments.

Inference orchestration could become as important as model selection for controlling AI economics.

💻 Robinhood Ventures Backs Cognition with $10 Million

Robinhood Ventures invested $10 million in Cognition, joining the coding-tool maker’s previously announced Series E. The investment highlights continued confidence in software agents that can assist with programming tasks, while extending Robinhood’s venture activity into infrastructure and productivity technologies shaping how developers build products.

Capital is flowing toward coding agents that promise measurable gains in software development productivity.

Disagree with one of today's takeaways? Reply and make your case.

Know someone drowning in AI noise? Send them your referral link

Reach data and AI leaders in this inbox: book a placement.